CN1253572C - 分离的结合hla－c分子的肽及其用途 - Google Patents

分离的结合hla－c分子的肽及其用途 Download PDF

Info

Publication number
CN1253572C
CN1253572C CNB018194818A CN01819481A CN1253572C CN 1253572 C CN1253572 C CN 1253572C CN B018194818 A CNB018194818 A CN B018194818A CN 01819481 A CN01819481 A CN 01819481A CN 1253572 C CN1253572 C CN 1253572C
Authority
CN
China
Prior art keywords
hla
cells
cell
peptide
eso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018194818A
Other languages
English (en)
Chinese (zh)
Other versions
CN1476480A (zh
Inventor
萨夏·格恩杰蒂克
劳埃德·J·奥尔德
永田康浩
埃尔克·贾格尔
陈耀桢
亚历山大·克努思
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Memorial Sloan Kettering Cancer Center
Ludwig Cancer Research
Original Assignee
Cornell Research Foundation Inc
Memorial Sloan Kettering Cancer Center
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc, Memorial Sloan Kettering Cancer Center, Ludwig Cancer Research filed Critical Cornell Research Foundation Inc
Publication of CN1476480A publication Critical patent/CN1476480A/zh
Application granted granted Critical
Publication of CN1253572C publication Critical patent/CN1253572C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB018194818A 2000-09-26 2001-09-24 分离的结合hla－c分子的肽及其用途 Expired - Fee Related CN1253572C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/670,456 US6506875B1 (en) 2000-09-26 2000-09-26 Isolated peptides which bind to HLA-C molecules and uses thereof
US09/670,456 2000-09-26

Publications (2)

Publication Number Publication Date
CN1476480A CN1476480A (zh) 2004-02-18
CN1253572C true CN1253572C (zh) 2006-04-26

Family

ID=24690468

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018194818A Expired - Fee Related CN1253572C (zh) 2000-09-26 2001-09-24 分离的结合hla－c分子的肽及其用途

Country Status (9)

Country Link
US (2) US6506875B1 (https=)
EP (1) EP1320609B1 (https=)
JP (1) JP4174570B2 (https=)
CN (1) CN1253572C (https=)
AT (1) ATE325876T1 (https=)
AU (2) AU2001293051B2 (https=)
CA (1) CA2423481C (https=)
DE (1) DE60119552T2 (https=)
WO (1) WO2002026778A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888100B2 (en) * 1996-10-03 2011-02-15 Memorial Sloan-Kettering Cancer Research Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
WO2014207708A2 (en) 2013-06-28 2014-12-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
CN105085616A (zh) * 2014-05-23 2015-11-25 上海市普陀区中心医院 一种氨基酸序列及其应用
CN105085615A (zh) * 2014-05-23 2015-11-25 上海市普陀区中心医院 一种多肽序列及其应用
BR112017013574A2 (pt) 2014-12-23 2018-03-06 Verdon Daniel conjugados de aminoácido e peptídeo e usos dos mesmos
EP3419962A4 (en) 2016-02-26 2020-03-11 Auckland Uniservices Limited CONJUGATES OF AMINO ACIDS AND PEPTIDES AND CONJUGATION METHOD
WO2020178738A1 (en) * 2019-03-04 2020-09-10 University Health Network T cell receptors and methods of use thereof
MX2021010541A (es) 2019-03-04 2021-12-15 Univ Health Network Receptores de linfocitos t y metodos de uso de estos.
CN113795586B (zh) 2019-03-25 2026-03-27 大学健康网络 T细胞受体及其使用方法
CN120397921B (zh) * 2025-05-28 2025-12-02 江苏新恒鼎装备制造有限公司 一种具有自锁功能的船用曲轴红套升降平台

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013481A (en) * 1993-07-22 2000-01-11 Ludwig Institute For Cancer Research Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
US6251603B1 (en) * 1996-10-03 2001-06-26 Ludwig Institute For Cancer Research Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
AU9572098A (en) * 1997-10-08 1999-04-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel human cancer antigen ny eso-1/cag-3 and gene encoding same
JP2002509859A (ja) * 1998-01-23 2002-04-02 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ Ｈｌａ−ａ２９分子に結合する単離ポリペプチド、それらをコードする分子である核酸、およびそれらの使用
WO2000020445A2 (en) * 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
WO2001062917A1 (en) * 2000-02-22 2001-08-30 Ludwig Institute For Cancer Research Isolated genomic sequences which encode the ny-eso-1 cancer testis tumor antigen and uses thereof

Also Published As

Publication number Publication date
JP4174570B2 (ja) 2008-11-05
DE60119552T2 (de) 2007-04-19
US7009035B2 (en) 2006-03-07
CN1476480A (zh) 2004-02-18
JP2004524271A (ja) 2004-08-12
EP1320609B1 (en) 2006-05-10
US20030050451A1 (en) 2003-03-13
AU9305101A (en) 2002-04-08
HK1060594A1 (en) 2004-08-13
AU2001293051B2 (en) 2007-04-26
ATE325876T1 (de) 2006-06-15
EP1320609A2 (en) 2003-06-25
CA2423481C (en) 2008-06-10
WO2002026778A3 (en) 2003-02-13
DE60119552D1 (de) 2006-06-14
WO2002026778A2 (en) 2002-04-04
US6506875B1 (en) 2003-01-14
CA2423481A1 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
FI121710B (fi) Melanooma-antigeeni
RU2464275C2 (ru) Пептидные вакцины для раков, экспрессирующих опухолеспецифические антигены
FI123050B (fi) Melanooma-antigeeni
JP3096739B2 (ja) Ｈｌａ分子によって提示される単離ノナペプチドとその使用
CN1151170C (zh) Mage肿瘤排斥抗原前体衍生的与hla-a2分子形成复合物的分离肽
JP2011200231A (ja) ヒト腫瘍抗原からの免疫原性ｔヘルパーエピトープおよび前記エピトープを使用する免疫療法の方法
JPH08507693A (ja) 腫瘍拒絶抗原先駆体をコード化する核酸分子
TW518340B (en) Tumor antigen peptide derivative
CN1313481C (zh) 结合hla分子的分离的九肽和十肽及其应用
CN1253572C (zh) 分离的结合hla－c分子的肽及其用途
CN1059466C (zh) 鉴定患有细胞异常性的个体的方法
US10765729B2 (en) Tumor antigen peptide
JP4436977B2 (ja) 新規な腫瘍抗原タンパク質ｓａｒｔ−３、およびその腫瘍抗原ペプチド
JP4365405B2 (ja) Ｍｈｃ分子と結合する腫瘍関連ペプチド
AU2001293051A1 (en) Isolated peptides which bind to HLA-C molecules and uses thereof
US7071294B1 (en) Tumor antigen protein art-1 and tumor antigen peptide thereof
EP1103561B1 (en) Hla-a2 restraint tumor antigen peptide originating in sart-1
HK1060594B (en) Isolated peptides which bind to hla-c molecules and uses thereof
US6838445B1 (en) Tumor antigen peptide originating in SART-1
HK1034980A (en) Tumor antigen peptide derivatives
HK1022276A (en) Isolated peptides which complex with hla-cw*16 molecules, and uses thereof
HK1037195A (en) Tumor antigen peptide originating in sart-1
HK1036996A (en) Hla-a2 restraint tumor antigen peptide originating in sart-1
JPWO2000006595A1 (ja) Ｓａｒｔ−１由来のｈｌａ−ａ２拘束性腫瘍抗原ペプチド

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: CORNEL RESEARCH FUND; MEMORIAL SLOAN-KETTERING CA

Free format text: FORMER OWNER: NONE

Effective date: 20040604

Owner name: LUDWIG INSTITUTE FOR CANCER RESEARCH;

Free format text: FORMER OWNER: LUDWIG INSTITUTE FOR CANCER RESEARCH

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20040604

Address after: American New York

Applicant after: Ludwig Inst. of Cancer Research

Co-applicant after: Cornell Research Foundation, Inc.

Co-applicant after: Memorial Sloan Kettering Cancer Center

Address before: American New York

Applicant before: Ludwig Inst. of Cancer Research

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1060594

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060426

Termination date: 20160924